About this episode

Inflammatory bowel disease (IBD) is a group of gastrointestinal conditions affecting almost 7 million people globally, and this incidence is rising. While treatments have improved over the last century, many patients do not respond sufficiently, especially those with moderate to severe levels of the disease. Novel drugs that restrain the immune system and reduce inflammation are being developed with the hope of improving patient outcomes. Dr Benjamin Misselwitz at Island Hospital of Bern and Bern University and his colleagues have conducted a comprehensive review of the emerging therapies and make recommendations for improving treatment for a wider range of patients.